<DOC>
	<DOCNO>NCT01030783</DOCNO>
	<brief_summary>This open-label , randomize , control , multi-national , multi-center , parallel-arm trial compare tivozanib sorafenib subject advance RCC . The study design compare PFS , OS , ORR , DR , safety tolerability , kidney specific symptoms/health outcome measurement tivozanib sorafenib .</brief_summary>
	<brief_title>A Study Compare Tivozanib ( AV-951 ) Sorafenib Subjects With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>This open-label , randomize , control , multi-national , multi-center , parallel-arm trial compare tivozanib sorafenib subject advance RCC . The study design compare PFS , OS , ORR , DR , safety tolerability , kidney specific symptoms/health outcome measurement tivozanib sorafenib . Subjects randomize ( 1:1 ) treatment tivozanib sorafenib stratify geographic region ( North America/Western Europe , Central/Eastern Europe , rest world ) ; number prior treatment ( 0 1 ) ; number metastatic sites/organs involve ( 1 ≥ 2 ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . ≥ 18years age . 2 . Subjects recurrent metastatic RCC . 3 . Subjects must undergo prior nephrectomy ( complete partial ) excision primary tumor . 4 . Histologically cytologically confirm RCC clear cell component ( subject pure papillary cell tumor nonclear cell histology , include collect duct , medullary , chromophobe , mixed tumor contain predominantly sarcomatoid cell , unclassified RCC exclude ) . 5 . Measurable disease per RECIST criterion Version 1.0 . 6 . Treatment naïve subject subject receive one prior systemic treatment ( immunotherapy , include interferonalfa interleukin2 base therapy , chemotherapy , hormonal therapy investigational agent ) metastatic RCC . Postoperative adjuvant systemic therapy count prior therapy unless recurrence detect within 6 month completion treatment , case count prior therapy metastatic disease . 7 . ECOG performance status 0 1 , life expectancy ≥ 3 month . 8 . If female childbearing potential , documentation negative pregnancy test prior enrollment . 9 . Ability give write informed consent comply protocol requirement . 1 . Any prior VEGFdirected therapy include VEGF antibody ( eg , bevacizumab ) , VEGF receptor tyrosine kinase inhibitor ( eg , sunitinib , sorafenib , axitinib , pazopanib , etc . ) , VEGF trap ( eg , aflibercept ) , agent investigational agent target VEGF pathway . 2 . Any prior therapy agent target mTOR pathway ( eg , temsirolimus , everolimus , etc ) 3 . Primary CNS malignancy CNS metastasis ; subject previously treat brain metastasis allow brain metastasis stable without steroid treatment least 3 month follow prior treatment ( radiotherapy surgery ) . 4 . Any hematologic abnormality ( note protocol ) . 5 . Any serum chemistry abnormality ( note protocol ) . 6 . Significant cardiovascular disease . 7 . Nonhealing wound , bone fracture , skin ulcer . 8 . Active peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , gastrointestinal condition increase risk perforation ; history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 4 week prior administration first dose study drug . 9 . Serious/active infection infection require parenteral antibiotic . 10 . Inadequate recovery prior surgical procedure major surgical procedure within 4 week prior administration first dose study drug . 11 . Significant thromboembolic vascular disorder within 6 month prior administration first dose study drug . 12 . Significant bleeding disorder within 6 month prior administration first dose study drug . 13 . Currently active second primary malignancy , include hematologic malignancy ( leukemia , lymphoma , multiple myeloma , etc . ) , nonmelanoma skin cancer , nonmetastatic prostate cancer , situ cervical cancer ductal lobular carcinoma situ breast . Subjects consider currently active malignancy complete anticancer therapy disease free &gt; 2 year . 14 . Pregnant lactating female . 15 . History genetic acquire immune suppression disease HIV ; subject immune suppressive therapy organ transplant . 16 . Lifethreatening illness organ system dysfunction compromise safety evaluation . 17 . Requirement hemodialysis peritoneal dialysis . 18 . Inability swallow pill , malabsorption syndrome gastrointestinal disease severely affect absorption tivozanib sorafenib , major resection stomach small bowel , gastric bypass procedure . 19 . Psychiatric disorder alter mental status precluding inform consent necessary testing . 20 . Sexually active premenopausal female subject ( female partner male subject ) must use adequate contraceptive measure , study 50 day last dose study drug . Sexually active male subject must use adequate contraceptive measure , study least 90 day last dose drug . All fertile male female subject partner must agree use highly effective method contraception ( include partner ) . Effective birth control include ( ) IUD plus one barrier method ; ( b ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . ( Note : Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , consider effective study . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>